| Literature DB >> 20003179 |
Nanfang Li1, Hongmei Wang, Jin Yang, Ling Zhou, Jing Hong, Yanying Guo, Wenli Luo, Jianhang Chang.
Abstract
BACKGROUND: Hypertension affects > 18.8% of adults in China. Indeed, hypertension is the most prevalent risk factor for cardiovascular morbidity and mortality worldwide. Genetic variation is thought to contribute to the etiology of hypertension. NEDD4L is a candidate gene for hypertension, both functionally and genetically. The purpose of the current study was to investigate the relationship between the variation in NEDD4L and essential hypertension in Kazakh, which is a relatively isolated population with a pure genetic background and is an ideal population to study genetic mechanisms of hypertension.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20003179 PMCID: PMC2801499 DOI: 10.1186/1471-2350-10-130
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Sequence variations in the promoter region and exons in Nedd4L identified in Kazakh hypertensive patients
| SNP name | Region | Amino acid substitution | Allele 1 freq | Allele 2 freq | Flanking sequence | Typing | db SNP ID |
|---|---|---|---|---|---|---|---|
| -608C>G | promoter | 0.9877 | 0.0123 | ||||
| -548G>A | promoter | 0.9813 | 0.0187 | ||||
| 271420T>C | intron6 | 0.5989 | 0.4011 | Taqman | rs2288774 | ||
| 271454A>G | intron6 | 0.7692 | 0.2308 | Taqman | rs2288775 | ||
| 296921-296923delTTG | intron13 | 0.7381 | 0.2619 | Taqman | |||
| 297071G>A | exon14 | R423R | 0.9909 | 0.0091 | |||
| 312644T>G | intron18 | 0.9731 | 0.0269 | ||||
| 312671C>T | intron18 | 0.9624 | 0.0376 | ||||
| 325828A>G | intron22 | 0.9765 | 0.0235 | ||||
| 340782G>C | intron24 | 0.9892 | 0.0108 | ||||
| 351555C>T | exon30 | A944A | 0.9944 | 0.0056 |
Sequence variations were screened in 94 hypertensive patients. Taqman, The single nucleotide polymorphism (SNP) was successfully genotyped by the Taqman method. The A of the ATG of the initiator Met codon is denoted nucleotide +1, as recommended by the Nomenclature Working Group (Hum Mut 1998; 11:1--3). The nucleotide sequence [NCBI: NM-015277] wasused as a reference sequence.
Basic characteristics of subjects in hypertensives and normotensives
| Total | Male | Female | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Control | Case | Control | Case | Control | Case | ||||
| Age | 42.04 ± 7.35 | 46.23 ± 7.63 | < 0.001* | 42.24 ± 7.48 | 46.11 ± 7.97 | < 0.001* | 41.90 ± 7.28 | 46.34 ± 7.37 | < 0.001* |
| BMI | 25.27 ± 3.55 | 28.14 ± 4.50 | < 0.001* | 25.39 ± 3.23 | 28.52 ± 4.22 | < 0.001* | 25.18 ± 3.76 | 27.83 ± 4.70 | < 0.001* |
| SBP | 117.78 ± 11.11 | 150.60 ± 25.90 | < 0.001* | 119.43 ± 10.58 | 149.28 ± 25.67 | < 0.001* | 116.65 ± 11.34 | 151.67 ± 26.11 | < 0.001* |
| DBP | 78.28 ± 7.53 | 96.88 ± 10.92 | < 0.001* | 80.29 ± 6.24 | 97.03 ± 10.45 | < 0.001* | 76.88 ± 8.04 | 96.76 ± 11.32 | < 0.001* |
| TC | 4.88 ± 1.00 | 5.14 ± 1.05 | < 0.001* | 5.09 ± 1.07 | 5.26 ± 1.03 | 0.111 | 4.84 ± 0.93 | 5.05 ± 1.06 | 0.001* |
| HDL | 1.47 ± 0.38 | 1.44 ± 0.39 | 0.244 | 1.31 ± 0.34 | 1.27 ± 0.31 | 0.244 | 1.58 ± 0.37 | 1.58 ± 0.40 | 0.927 |
| TG | 1.00 ± 0.60 | 1.23 ± 0.74 | < 0.001* | 1.23 ± 0.75 | 1.53 ± 0.91 | 0.001* | 0.85 ± 0.43 | 0.99 ± 0.46 | 0.001* |
| FBG | 4.83 ± 0.65 | 5.08 ± 1.35 | 0.001* | 4.95 ± 0.63 | 5.21 ± 1.59 | 0.050 | 4.75 ± 0.65 | 4.98 ± 1.12 | 0.008* |
| UNa rate (uM/min) | 163.78 ± 85.55 | 171.14 ± 87.57 | 0.260 | 182.64 ± 93.98 | 190.79 ± 88.33 | 0.439 | 150.31 ± 76.39 | 155.27 ± 83.90 | 0.536 |
| Pl Na (mmol/L) | 144.57 ± 8.98 | 144.74 ± 8.75 | 0.785 | 145.91 ± 9.32 | 145.09 ± 7.34 | 0.353 | 143.67 ± 8.66 | 144.45 ± 9.74 | 0.338 |
| Life style | |||||||||
| Smoking | 22.8 | 24.3 | 0.606 | 55.4 | 52.6 | 0.593 | 0.3 | 1.4 | 0.176 |
| Drinking | 21.6 | 21.1 | 0.871 | 52.0 | 44.4 | 0.147 | 0.7 | 2.4 | 0.109 |
| Present illness | |||||||||
| Overweight (%) | 49.9 | 74.3 | 0.000* | 53.1 | 79.8 | 0.000* | 47.7 | 69.8 | 0.000* |
| Dyslipidemia (%) | 38.9 | 53.4 | 0.000* | 60.0 | 68.8 | 0.078 | 24.7 | 41.0 | 0.000* |
| Hyperglycemia (%) | 16.7 | 25.2 | 0.002* | 15.5 | 23.5 | 0.057 | 17.4 | 26.6 | 0.014* |
BMI; body mass index, SBP; systolic blood pressure, DBP; diastolic blood pressure, TC; total cholesterol, HDL-c; high-density lipoprotein cholesterol. TG; triglyceride, FBG; fasting blood glucose, Una rate; urinary Na excretion rate, PlNa; plasma Na. Values are mean ± SD or percentage. P < 0.05 was considered significant. The differences between case and control group were performed by t-test or X2 test.
* P < 0.05
Genotype and allele distributions in patients with essential hypertension and in control individuals
| Total | Male | Female | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SNPs | Genotype | Case (n = 383) | Control (n = 500) | Case (n = 171) | Control (n = 204) | Case (n = 212) | Control (n = 296) | |||
| rs2288774 n(%) | ||||||||||
| Additive model | T/T | 123 | 177 (35.8) | 0.365 | 60 (35.7) | 71 (35.1) | 0.661 | 63 (30.0) | 106 (36.2) | 0.296 |
| C/T | 173 | 228 (46.1) | 76 (45.2) | 99 (49.0) | 97 (46.2) | 129 (44.0) | ||||
| C/C | 82 (21.7) | 90 (18.1) | 32 (19.1) | 32 (15.9) | 50 (23.8) | 58 (19.8) | ||||
| Dominant model | T/T | 123 | 177 (35.8) | 0.984 | 60 (35.7) | 71 (35.1) | 0.909 | 63 (30.0) | 106 (36.2) | 0.148 |
| T/C+C/C | 255 | 318 (64.2) | 108 (64.3) | 131 (64.9) | 147 (70.0) | 187 (63.8) | ||||
| Recessive model | T/T+C/T | 296 | 405 (81.9) | 0.192 | 136 (80.9) | 170 (84.1) | 0.417 | 160 (76.2) | 235 (80.2) | 0.279 |
| C/C | 82 (21.7) | 90 (18.1) | 32 (19.1) | 32 (15.9) | 50 (23.8) | 58 (19.8) | ||||
| Allele | T | 419 | 582 (58.8) | 0.159 | 196 (58.3) | 241 (59.7) | 0.716 | 223 (53.1) | 341 (58.2) | 0.108 |
| C | 337 | 409 (41.2) | 140 (41.7) | 163 (40.3) | 197 (46.9) | 245 (41.8) | ||||
| rs2288775 n(%) | ||||||||||
| Additive model | A/A | 210 | 302 (60.9) | 0.189 | 100 (58.8) | 122 (60.7) | 0.901 | 110 (51.9) | 180 (61.0) | 0.114 |
| A/G | 146 | 168 (33.9) | 61 (35.9) | 70 (34.8) | 85 (40.1) | 98 (33.2) | ||||
| G/G | 26 (6.8) | 26 (5.2) | 9 (5.3) | 9 (4.5) | 17 (8.0) | 17 (5.8) | ||||
| Dominant model | A/A | 210 | 302 (60.9) | 0.078 | 100 (58.8) | 122 (60.7) | 0.714 | 110 (51.9) | 180 (61.0) | 0.040* |
| A/G+G/G | 172 | 194 (39.1) | 70 (41.2) | 79 (39.3) | 102 (48.1) | 115 (39.0) | ||||
| Recessive model | A/A+AG | 356 | 470 (94.8) | 0.948 | 161 (94.7) | 192 (95.5) | 0.715 | 195 (92.0) | 278 (94.2) | 0.316 |
| G/G | 26 (6.8) | 26 (5.2) | 9 (5.3) | 9 (4.5) | 17 (8.0) | 17 (5.8) | ||||
| Allele | A | 566 | 772 (77.8) | 0.065 | 261 (76.8) | 314 (78.1) | 0.662 | 305 (71.9) | 458 (77.6) | 0.038* |
| G | 198 | 220 (22.2) | 79 (23.2) | 88 (21.9) | 119 (28.1) | 132 (22.4) | ||||
| 296921-296923 delTTG n(%) | ||||||||||
| Additive model | I/I | 186 | 258 (52.3) | 0.217 | 91 (53.5) | 111 (54.7) | 0.674 | 95 (45.0) | 147 (50.7) | 0.024* |
| I/D | 155 | 199 (40.4) | 69 (40.6) | 76 (37.4) | 86 (40.8) | 123 (42.4) | ||||
| D/D | 40 (10.5) | 36 (7.3) | 10 (5.9) | 16 (7.9) | 30 (14.2) | 20 (6.9) | ||||
| Dominant model | I/I | 186 | 258 (52.3) | 0.303 | 91 (53.5) | 111 (54.7) | 0.824 | 95 (45.0) | 147 (50.7) | 0.210 |
| D/D+I/D | 195 | 235 (47.7) | 79 (46.5) | 92 (45.3) | 116 (55.0) | 143 (49.3) | ||||
| Recessive model | I/I+I/D | 341 | 457 (92.7) | 0.096 | 160 (94.1) | 187 (92.1) | 0.450 | 181 (85.8) | 270 (93.1) | 0.007* |
| D/D | 40 (10.5) | 36 (7.3) | 10 (5.9) | 16 (7.9) | 30 (14.2) | 20 (6.9) | ||||
| Allele | I | 527 | 715 (72.5) | 0.125 | 251 (73.8) | 298 (73.4) | 0.896 | 276 (65.4) | 417 (71.9) | 0.028* |
| D | 235 | 271 (27.5) | 89 (26.2) | 108 (26.6) | 146 (34.6) | 163 (28.1) | ||||
* P < 0.05
Odds ratios and 95% confidence intervals for two variations of NEDD4L gene associated with essential hypertension in female after adjusting smoking, drinking, age and obesity
| polymorphism | genotype | odds ratios | 95% confidence interval | |
|---|---|---|---|---|
| rs2288775 | A/A | 1 | ||
| A/G+G/G | 1.479 | 1.011-2.064 | 0.044* | |
| 296921-296923delTTG | II+ID | 1 | ||
| D/D | 1.908 | 1.020-3.568 | 0.043* |
* P < 0.05
Haplotype analysis in patients with essential hypertension and control participants
| Haplotype | Total | Male | Female | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 296921-3delTTG | rs2288774 | rs2288775 | Case | Control | Case | Control | Case | Control | ||||
| H1 | I | T | A | 0.526 | 0.558 | 0.190 | 0.562 | 0.565 | 1.000 | 0.497 | 0.554 | 0.087 |
| H2 | D | C | G | 0.229 | 0.192 | 0.058 | 0.190 | 0.185 | 0.913 | 0.260 | 0.197 | 0.020* |
| H3 | I | C | A | 0.136 | 0.140 | 0.856 | 0.140 | 0.135 | 0.924 | 0.134 | 0.143 | 0.718 |
| H4 | D | C | A | 0.050 | 0.053 | 0.825 | 0.044 | 0.055 | 0.595 | 0.054 | 0.052 | 0.899 |
* P < 0.05
Comparing of urinary Na excretion rate and plasma Na between different genotypes by Covariate variance analysis adjusting for age, smoking, and drinking.
| 296921-296923delTTG | Rs2288775 | |||||
|---|---|---|---|---|---|---|
| I/I+I/D | D/D | A/A | A/G+G/G | |||
| UNa rate (uM/min) | ||||||
| Total | 169.27 ± 87.71 | 143.92 ± 69.00 | 0.027* | 167.69 ± 86.10 | 166.86 ± 87.43 | 0.954 |
| Male | 186.75 ± 92.03 | 180.50 ± 83.87 | 0.798 | 182.82 ± 91.23 | 193.80 ± 91.83 | 0.278 |
| Female | 155.50 ± 81.69 | 126.49 ± 53.47 | 0.032* | 156.21 ± 80.32 | 147.25 ± 78.73 | 0.233 |
| Pl Na (mmol/L) | ||||||
| Total | 144.69 ± 8.83 | 144.11 ± 9.62 | 0.496 | 144.67 ± 8.46 | 144.58 ± 9.49 | 0.900 |
| Male | 145.67 ± 8.61 | 143.65 ± 6.02 | 0.238 | 145.22 ± 7.08 | 145.98 ± 10.27 | 0.330 |
| Female | 143.94 ± 8.93 | 144.34 ± 11.09 | 0.846 | 144.25 ± 9.36 | 143.63 ± 8.83 | 0.471 |
Una rate; urinary Na excretion rate, PlNa; plasma Na. * P < 0.05